Medical Writing. Much has been said about the introduction of biosimilars in Spain in recent years, even more so since the appearance of the first monoclonal antibodies. Its price and the mistrust it generates as it is new ground to tread on (as happened with generics years ago), led many of its defenders to advocate a quota system in hospitals, pointing out that this has already been done in Germany to encourage its introduction into the system.